GAITHERSBURG, MD, September 23, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry. “We’re thrilled […]
Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer
Adaptive Phage Therapeutics Adds Jesse L. Goodman, M.D., M.P.H., to its Board of Directors
GAITHERSBURG, MD, September 14, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Jesse L. Goodman, MD, MPH, to the company’s Board of Directors. “Jesse has already made significant contributions to APT as an advisor and, as such, we are thrilled to have […]
Adaptive Phage Therapeutics Highlights the Publication of a Case Study of Investigational Phage Therapy for an Antibiotic-Resistant Bacterial Infection in a Child
7-year-old child acquired antibiotic-resistant chronic Pseudomonas aeruginosa infection of her lower leg following injury sustained in a car accident Prior surgical debridement, hardware removal and three months of IV antibiotics had failed to stop the progress of infection – no other medical or surgical options were available. Pain-free weight bearing on the affected leg was achieved for […]
Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
– License to expanding phage library compiled at the Walter Reed Army Institute of Research – – Adaptive Phage Therapeutics is now engaged with two branches of the U.S. Military – GAITHERSBURG, MD., August 31, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has […]
Adaptive Phage Therapeutics to Present at the FDA and NIH Hosted Workshop on Science and Regulation of Bacteriophage Therapy
GAITHERSBURG, MD, August 24, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that Robert Hopkins, MD, Chief Medical Officer, will present at the upcoming Science and Regulation of Bacteriophage Therapy Workshop, hosted by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and […]
Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer
– – Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, is a highly regarded medical and research professional in infectious diseases with over 25 years of industry experience -Evan Loh, M.D., Jonathan Leff, and Jana Jensen, Ph.D., Appointed Directors of APT- GAITHERSBURG, MD, July 30, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company […]
Adaptive Phage Therapeutics Expands Board Following Series B Financing led by Deerfield Management
– Evan Loh, M.D., Jonathan Leff, and Jana Jensen, Ph.D., Appointed Directors of APT- GAITHERSBURG, MD, June 29, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), Jonathan Leff, Partner at Deerfield Management, […]
Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases
Collaboration planned to develop therapeutics potentially targeting multiple ophthalmic diseases leveraging APT’s PhageBank™ technology GAITHERSBURG, MD, June 10, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a newly-formed research collaboration with Oyster Point Pharma, Inc. (Nasdaq: OYST) for developing therapies, using APT’s PhageBank™ technology, potentially targeting […]
Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank™ in Urinary Tract Infections
GAITHERSBURG, Md., June 3, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in a Phase 1/2 study of bacteriophage therapy (PhageBank™) to evaluate the safety, tolerability, and efficacy of targeted, personalized, bacteriophage (“phage”) treatments in patients with urinary […]
Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing
GAITHERSBURG, MD., May 11, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed […]